Loganzo and colleagues [116], for example, used many cycles of anti-HER2 trastuzumab–maytansinoid ADC therapy to generate a variety of T-DM1-resistant breast cancer cell lines. This evidence concerns the gene ERBB2 and breast carcinoma.